The research centre focuses on brain cancer in adult patients. The most common tumour types are gliomas, which are categorised as low-grade or high-grade. The higher the grade, the poorer the prognosis. Survival among patients with glioblastoma, the most aggressive and most common type of brain cancer, has not improved significantly over the past 15 years. Half of the patients die within 20 months of diagnosis, and the five-year survival rate is just 10%.

The centre’s overall aim is therefore to improve and prolong survival.

Initially, this aim will be pursued by mapping the genomes of several brain tumours and systematically collecting data on the effect of treatments. The ambition is to achieve a giant leap forward in the future prospects of patients.

Survival will be prolonged through translational and cross-disciplinary research, in which basic and clinical researchers work together to identify new targeted treatments. At the same time, the centre works to improve surgical and diagnostic procedures and to explore new intra-operative treatments. The centre will develop and test new drug candidates in preclinical models and establish new and innovative national investigator-initiated phase I/II clinical trials.

Based on the data collected, the centre will create a database of real-world data and real-world evidence, which will be used to study the causal relationship between diagnosis, treatment and effect. In this way, the centre will generate knowledge on how to improve survival among patients with brain cancer.

Stay up to date with the centre’s activities and news.

Organisation

Organisation chart
Organisation chart
Click the illustration to enlarge it
Click the illustration to enlarge it

The organisation of the project and governance. The programme is organised into a Project Coordination team (Board of Directors) coordinating the overall structure and key decisions of the project. A Steering Group is composed of Principal Investigators and work package leaders, and is responsible for the coordination between the WPs, and ensures the project’s short- and long-term progress. The Steering Group is also represented by a patient and the Danish Brain Tumor Association.

Diagnosis molecular profiling

  • WP1: Molecular characterisation and identification of clonal evolution
  • WP2: Ex vivo high-throughput drug screening of GBM patient-derived cells
  • WP3: Identification and profiling of malignant, migratory cells
  • WP4: Precision medicine for GBM patients
  • WP5: Identification and validation of novel therapeutic targets
  • WP6: Monitoring cell-free DNA in plasma and tracking tumour mutations in tissue and sequential plasma samples in patients with newly diagnosed brain cancer

Treatment

  • WP7: Nanocarrier-based drug delivery for next-generation glioblastoma therapy
  • WP8: Magnetic Resonance guided Laser Interstitial Thermal Therapy (MRgLITT) as supplementary treatment for brain cancer
  • WP9: Synaptic input to brain tumours in humans: potential implications for tumour growth, epilepsy and cancer treatment
  • WP10: Personalised radiotherapy for GBM
  • WP11: National Quality Assurance programme for radiotherapy delineation
  • WP12: Radiotherapy and advanced imaging
  • WP13: Antibody-drug conjugate based GBM targeting approach
  • WP14: Selection of targeted therapies and clinical trials
  • WP15: ProTarget: A Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on Genomic Profiling
  • WP16: Theranostics and molecular imaging for glioblastoma

Data collection, interpretation and modelling

  • WP17: Non-interventional study and collection of real-world data (RWD)
  • WP18: Shared decision-making in glioblastoma patients: treatment decisions, patient involvement, and emotional wellbeing
  • WP19: Physiological MRI for treatment prognosis and response monitoring of GBM
  • WP20: Patient-centric data modelling